Group items tagged

"The global voice and speech recognition software market size is anticipated to reach USD 31.82 billion by 2025. It is anticipated to register a CAGR of 17.5% during the forecast period. The market is anticipated to witness an upsurge in the adoption of voice activated systems, voice-enabled devices, and voice-enabled virtual assistant systems owing to the rising application in the banking and automobile sectors. The escalating need to counter fraudulent activities and to enhance security in the banking sector is projected to boost the adoption of voice biometrics for user authentication."

The global breast cancer drug market size is expected to reach USD 38.4 billion by 2025. It is projected to expand at a CAGR of 10.7% during the forecast period. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends stoking market growth. Global breast cancer drugs market is expected to grow lucratively as many players focus majorly on R&D of innovative treatments. They engage in extensive research to develop novel drugs for the treatment of the disease to gain a higher market share. There exists a growing pressure and need for novel therapies and treatment due to rapidly accelerating prevalence of diseases. The strong pipeline is expected to provide new and effective treatment options and improved outcomes than existing therapies. With advancements in drug delivery systems, various target specific therapies have been customized and designed as a carrier to infuse the therapeutic agent to the target site. Carriers for inducing target therapy include modified anticancer agent's specific to molecular-recognition-element, anticancer peptides, and nanoparticle-based anticancer drugs. For instance, HER2/neu protein is usually given in combination with other anti-cancer drugs in targeted therapy. Get Free Sample Copy of this Report at at: https://www.radiantinsights.com/research/breast-cancer-drugs-market/request-sample F. Hoffman-La Roche Ltd leads the breast cancer drugs market with Herceptin, Perjeta, and Kadcyla. However, rapid advancements in biosimilars with a goal to offer cost effective alternatives to patients is anticipated to put pressure on this space. For instance, in December 2017, the Food and Drug Administration (FDA) approved the first biosimilar of trastuzumab for HER2+ breast cancer. Further key findings from the report suggest: * HER2 inhibitors is expected to be the most preferred drug class segment over the forecast period, owing to their high specificity as they are subclass of target therapy *